

# WHAT ID IS DOING TO PRESERVE ANTIBIOTICS

The rapid increase of antibiotic resistance coupled with no new drugs to treat infections has created a perfect storm.

Every current antibiotic is a derivative of one discovered **before 1982.**



**\$1.8 billion**

Antimicrobial venture capital investment

**\$38 billion**

Total pharmaceutical venture capital investment

**Less than 5%** of pharmaceutical venture capital goes to antimicrobials.



Most major drug companies have **reduced or quit** antibiotic research and development.

Compared to other types of drugs, antibiotics to treat resistant infections are difficult to develop.



Sales of antibiotics are

**small**

compared to other pharmaceuticals.

AVYCAZ (antibiotic)

**\$75 million**

in sales  
2 years post launch

MOST OTHER DRUGS

**\$500 million**

to **\$1 billion**

in sales  
2 years post launch

## ID'S RESPONSE

As new infectious diseases threats continue to emerge, we need a robust, renewable antibiotic pipeline to meet current and future patient and public health needs.

- **Remove barriers to developer entry** by affecting the cost of R&D investments
- **Provide incentives that offer financial return** after a technology has been developed